Ellen Linnea Freese Ballegaard

Ellen Linnea Freese Ballegaard

Auto-generated profile, based on publicly available information

Ellen Linnea Freese Ballegaard

Department of Nephrology and Endocrinology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2021 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
NCNicholas Carlson
Nicholas Carlson
KNKarl Emil Nelveg-Kristensen
Karl Emil Nelveg-Kristensen
EBEllen Freese Ballegaard
Ellen Freese Ballegaard
BFBo Feldt-Rasmussen
Bo Feldt-Rasmussen
MHMads Hornum
Mads Hornum
CTChristian Torp‐Pedersen
Christian Torp‐Pedersen

15 February 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
EBEllen Linnea Freese Ballegaard
Ellen Linnea Freese Ballegaard
JOJonas Bjerring Olesen
Jonas Bjerring Olesen
AKAnne-Lise Kamper
Anne-Lise Kamper
BFBo Feldt-Rasmussen
Bo Feldt-Rasmussen
GGGunnar Gislason
Gunnar Gislason
NCNicholas Carlson
Nicholas Carlson
The net benefit of oral anticoagulation (OAC) with vitamin K antagonists or direct oral anticoagulants in patients with advanced chronic kidney disease and atrial fibrillation remains uncertain. We examined the use, efficacy, and safety of OAC in patients with estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 (including dialysis-treated patients) and atrial fibrillation. In a retrospective cohort study, patients diagnosed with atrial fibrillation and eGFR of <30 mL/min/1.73 m2 were identified in national Danish registers between 2010 and 2022. Initiation of OAC was identified based on redemption of a relevant prescription. One-year risks of thromboembolic event, major bleeding, and death associated with OAC and no treatment were computed and standardized to the distribution of risk factors in the sample based on hazards determined in multiple Cox regression models adjusted for age and sex. A total of 3208 patients were included (mean age 80 years, 52.8% males, 20.9% chronic dialysis). OAC was initiated in 1375 (42.9%) patients, of whom 48.1% were vitamin K antagonists and 51.9% were direct oral anticoagulants. One-year risks in nontreated and anticoagulated patients were 4.8% (95% CI, 3.8%-5.7%) and 3.6% (95% CI, 2.8%-4.6%; P = .028) for thromboembolic event, 7.6% (95% CI, 6.6%-8.7%) and 10.5% (95% CI, 9.3%-12.1%; P < .001) for major bleeding, and 36.3% (95% CI, 34.2%-38.3%) and 29.6% (95% CI, 27.6%-31.6%; P < .001) for death, respectively. In a retrospective study on patients with advanced chronic kidney disease and atrial fibrillation, OAC was associated with overall decreased 1-year risk of thromboembolic event and death offset by increased 1-year risk of major bleeding.

18 July 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
EBEllen Linnea Freese Ballegaard
Ellen Linnea Freese Ballegaard
EGErik Lerkevang Grove
Erik Lerkevang Grove
AKAnne-Lise Kamper
Anne-Lise Kamper
BFBo Feldt-Rasmussen
Bo Feldt-Rasmussen
GGGunnar Gislason
Gunnar Gislason
NCNicholas Carlson
Nicholas Carlson
Key Points: Retrospective study of guideline-directed management of myocardial infarction in patients with and without CKD from 2010 to 2022. CKD was associated with lower rate of guideline-directed management and worse prognosis. Uptake of guideline-directed management increased and prognosis improved in both groups during the study period. Background: CKD is present in >30% of patients with acute myocardial infarction (MI) and has been associated with lower rates of guideline-directed management and worse prognosis. We investigated the use of guideline-directed management and mortality risk in patients with and without CKD. Methods: A nationwide cohort study based on health care registers encompassing all patients ≥18 years hospitalized with first-time MI in Denmark from 2010 to 2022 was conducted. CKD was defined as an eGFR <60 ml/min per 1.73 m2. Probability of guideline-directed management and risk of all-cause mortality in patients with and without CKD were calculated from adjusted multivariable logistic and Cox regression models with probabilities and risks standardized to the distribution of confounders in the population. Results: In total, we identified 21,009 patients who met eligibility criteria. The median age was 72 years, and 61% of patients were male; the median eGFR was 82 ml/min per 1.73 m2, and 21% of patients had CKD. The 30-day probabilities of coronary angiography and revascularization were 71% (95% confidence interval [CI], 69% to 72%) and 78% (95% CI, 77% to 79%), P < 0.001 and 52% (95% CI, 50% to 54%) and 58% (95% CI, 58% to 59%), P < 0.001, in patients with and without CKD, respectively. Probabilities increased during the study period (P for trend 0.05, 0.03, 0.02, and 0.03, respectively). In patients with and without CKD, the probability of dual antiplatelet therapy was 67% (95% CI, 65% to 68%) and 70% (95% CI, 69% to 71%), P = 0.001, whereas the probability of lipid-lowering treatment was 76% (95% CI, 75% to 78%) and 82% (95% CI, 81% to 83%), P < 0.001, respectively. The associated 1-year mortality was 21% (95% CI, 20% to 22%) and 16.4% (95% CI, 16% to 17%) in patients with and without CKD, respectively. with decreasing mortality rates in both groups during the study period (P for trend 0.03 and 0.01). Conclusions: Although survival after MI improved for all patients, CKD continued to be associated with lower use of guideline-directed management and higher mortality.

26 February 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
EBEllen Linnea Freese Ballegaard
Ellen Linnea Freese Ballegaard
KLKristine Lindhard
Kristine Lindhard
MLMorten Lindhardt
Morten Lindhardt
CPChristian Daugaard Peters
Christian Daugaard Peters
FNFinn Thomsen Nielsen
Finn Thomsen Nielsen
NCNicholas Carlson
Nicholas Carlson
Introduction Atrial fibrillation is highly prevalent in patients on chronic dialysis. It is unclear whether anticoagulant therapy for stroke prevention is beneficial in these patients. Vitamin K-antagonists (VKA) remain the predominant anticoagulant choice. Importantly, anticoagulation remains inconsistently used and a possible benefit remains untested in randomised clinical trials comparing oral anticoagulation with no treatment in patients on chronic dialysis. The Danish Warfarin-Dialysis (DANWARD) trial aims to investigate the safety and efficacy of VKAs in patients with atrial fibrillation on chronic dialysis. The hypothesis is that VKA treatment compared with no treatment is associated with stroke risk reduction and overall benefit. Methods and analysis The DANWARD trial is an investigator-initiated trial at 13 Danish dialysis centres. In an open-label randomised clinical trial study design, a total of 718 patients with atrial fibrillation on chronic dialysis will be randomised in a 1:1 ratio to receive either standard dose VKA targeting an international normalised ratio of 2.0–3.0 or no oral anticoagulation. Principal analyses will compare the risk of a primary efficacy endpoint, stroke or transient ischaemic attack and a primary safety endpoint, major bleeding, in patients allocated to VKA treatment and no treatment, respectively. The first patient was randomised in October 2019. Patients will be followed until 1 year after the inclusion of the last patient. Ethics and dissemination The study protocol was approved by the Regional Research Ethics Committee (journal number H-18050839) and the Danish Medicines Agency (case number 2018101877). The trial is conducted in accordance with the Helsinki declaration and standards of Good Clinical Practice. Study results will be disseminated to participating sites, at research conferences and in peer-reviewed journals. Trial registration numbers NCT03862859, EUDRA-CT 2018-000484-86 and CTIS ID 2022-502500-75-00.

13 June 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
EBEllen Linnea Freese Ballegaard
Ellen Linnea Freese Ballegaard
NCNicholas Carlson
Nicholas Carlson
MJMorten Buus Jørgensen
Morten Buus Jørgensen
ISIda Maria Hjelm Sørensen
Ida Maria Hjelm Sørensen
HTHelene Trankjær
Helene Trankjær
FGfor The Copenhagen CKD Cohort Study Group
for The Copenhagen CKD Cohort Study Group
Although cardiovascular morbidity and mortality are substantial in patients with chronic kidney disease (CKD), guideline-directed treatment of cardiovascular risk factors remains a challenge. Observational, cross-sectional study including patients aged 30–75 years with CKD stage 1–5 without kidney replacement therapy from a tertiary hospital outpatient clinic. Data were obtained through patient interview, clinical examination, biochemical work-up, and evaluation of medical records and prescription redemptions. Guideline-directed treatment was evaluated as pharmacological interventions: antihypertensive and lipid-lowering therapy including adverse effects and adherence estimated as medication possession ratio (MPR); and non-pharmacological interventions: smoking status, alcohol consumption, body mass index (BMI), and physical activity. The cohort comprised 741 patients, mean age 58 years, 61.4% male, 50.6% CKD stage 3, 61.0% office blood pressure ≤140/90 mmHg. Antihypertensives were prescribed to 87.0%, median number of medications 2 (IQR 1;3), 70.1% received renin–angiotensin system inhibition, 25.9% reported adverse effects. Non-adherence (MPR < 80%) was present in 23.4% and associated with elevated blood pressure (OR 1.53 (95% CI 1.03;2.27)) and increased urinary albumin excretion, P < 0.001. Lipid-lowering treatment was prescribed to 54.0% of eligible patients, 11.1% reported adverse effects, and 28.5% were non-adherent, which was associated with higher LDL cholesterol, P = 0.036. Overall, 19.2% were current smokers, 16.7% overconsumed alcohol according to Danish health authority recommendations 69.3% had BMI ≥ 25 kg/m2, and 38.3% were physically active <4 hours/week. Among patients prescribed antihypertensives, 51.9% reported having received advice on non-pharmacological interventions. Improved management of cardiovascular risk in patients with CKD entails intensified medical treatment and increased focus on patient adherence and non-pharmacological interventions.

17 May 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
CTClara Sophie Turner
Clara Sophie Turner
MHMads Hornum
Mads Hornum
EBEllen Linnea Freese Ballegaard
Ellen Linnea Freese Ballegaard
NCNicholas Carlson
Nicholas Carlson
SHSteffen Heegaard
Steffen Heegaard
DKDea H. Kofod
Dea H. Kofod
Although albuminuria is an established prognostic marker in individuals with diabetes and chronic kidney disease (CKD), less is known about the association between albuminuria and retinal and neurological complications in large, unselected populations with type 2 diabetes and established CKD. We investigated the association of urine albumin-creatinine-ratio (UACR) on prevalence and incidence of microvascular complications in individuals with CKD. We included 27,924 adults with type 2 diabetes and CKD (eGFR < 60 ml min⁻1 1.73 m2⁻1) from Danish health care registers (2010-2023). Outcomes included diabetic retinopathy, polyneuropathy, and progression of CKD. Odds of retinopathy and polyneuropathy at baseline were evaluated using logistic regressions. Standardized 5-year risks of outcomes ere estimated using Cox regressions across UACR strata (1000 mg/g). Median age was 75 years (IQR 69-80), 41.5% were female, and median eGFR was 53 ml min⁻1 1.73 m2⁻1 (IQR 47-56). Odds ratios for diabetic retinopathy and polyneuropathy were positively correlated with UACR. 5-year risks (95% CI) of all outcomes were similarly associated with increasing UACR levels. Albuminuria was associated with a progressive increase in prevalence and incidence of microvascular disease in individuals with type 2 diabetes and CKD.